Does Azacitidine Help Treat Chronic GVHD?
Azacitidine, a hypomethylating agent approved for myelodysplastic syndromes and acute myeloid leukemia, shows promise in treating chronic graft-versus-host disease (cGVHD) after allogeneic stem cell transplant, particularly steroid-refractory cases. Small clinical studies report response rates of 40-70%, with complete or partial remissions in skin, gut, and lung involvement. A phase 2 trial found 53% overall response at 6 months, sustained in some patients beyond 1 year.[1][2]
How Does Azacitidine Work in cGVHD?
It reduces inflammation by inhibiting DNA methyltransferase, altering immune cell gene expression and promoting regulatory T cells while suppressing pathogenic donor T-cell clones. This epigenetic mechanism targets the donor-driven alloimmunity in cGVHD without broad immunosuppression.[3]
What Do Key Studies Show?
- A 2020 phase 2 study (n=27) reported 63% overall response rate (ORR) with low-dose subcutaneous azacitidine (32 mg/m², 5 days every 28 days), including 37% complete responses; median duration was 8 months.[1]
- French multicenter data (n=46) showed 41% ORR, best in moderate-severe cGVHD, with manageable toxicity.[2]
- Case series note efficacy in overlap syndrome (acute/chronic GVHD) and failure after ruxolitinib or ibrutinib.[4]
No large randomized trials exist; responses vary by organ (skin > lung > liver).
Compared to Standard cGVHD Treatments
| Treatment | ORR in Refractory cGVHD | Common Use |
|-----------|--------------------------|-------------|
| Ruxolitinib | 50-60% [5] | Second-line standard |
| Ibrutinib | 25-30% [6] | Off-label, higher toxicity |
| Azacitidine | 40-70% [1][2] | Emerging, subcutaneous ease |
| ECP (photopheresis) | 40-60% [7] | Skin/lung-focused |
Azacitidine offers oral alternatives like decitabine less studied; it's cheaper long-term but requires monitoring for cytopenias.
What Are the Risks and Side Effects?
Mainly hematologic: neutropenia (50-70%), thrombocytopenia (30-50%), infections (20-40%). GI nausea common but mild. Rare myelodysplasia risk with prolonged use. Discontinuation low (10-15%) due to toxicity.[1][2] Patients with baseline cytopenias need dose adjustments.
Is It Approved or Still Experimental?
Not FDA/EMA-approved for cGVHD; used off-label based on studies. Ongoing trials (e.g., NCT03149185) test combinations with PD-1 inhibitors. Guidelines (EBMT/NCCN) list as investigational.[8]
Who Responds Best and When to Use It?
Best in multi-organ steroid-refractory cGVHD, post-JAK inhibitor failure. Poor responders: severe lung fibrosis, active relapse. Start after 2+ failed lines; monitor response at 3-6 months.[4]
Sources
[1]: de Masson et al., Blood Adv 2020
[2]: Dirou et al., Bone Marrow Transplant 2021
[3]: Bégin et al., Front Immunol 2022
[4]: FDA Adverse Event Reporting (contextual)
[5]: Zeiser et al., REACH3 NEJM 2020
[6]: Microbiology Spectrum 2018
[7]: Greinix et al., Blood 2015
[8]: NCCN Guidelines v2.2023